# External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA

> **NCT05495204** · — · COMPLETED · sponsor: **Epividian** · enrollment: 141 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Ibalizumab

## Key facts

- **NCT ID:** NCT05495204
- **Lead sponsor:** Epividian
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-05
- **Primary completion:** 2023-02-20
- **Final completion:** 2023-02-20
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05495204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05495204, "External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05495204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*